Medical Developments International (ASX:MVP) Cash-to-Debt

: 6.47 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medical Developments International's cash to debt ratio for the quarter that ended in Dec. 2023 was 6.47.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Medical Developments International could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Medical Developments International's Cash-to-Debt or its related term are showing as below:

ASX:MVP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 8.44 Max: 140.77
Current: 6.47

During the past 13 years, Medical Developments International's highest Cash to Debt Ratio was 140.77. The lowest was 0.09. And the median was 8.44.

ASX:MVP's Cash-to-Debt is ranked better than
73.07% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs ASX:MVP: 6.47

Medical Developments International Cash-to-Debt Historical Data

The historical data trend for Medical Developments International's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Medical Developments International Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

140.77

4.63

11.90

7.25

9.63

Medical Developments International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt																9.64	7.25	13.80	9.63	6.47

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medical Developments International Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Cash-to-Debt falls into.

Medical Developments International Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Medical Developments International's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.661	/	(0.352	+	2.208)
	=	9.63

Medical Developments International's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.699	/	(0.365	+	2.061)
	=	6.47

Medical Developments International (ASX:MVP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Medical Developments International Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Medical Developments International's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medical Developments International (ASX:MVP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Caribbean Drive, Scoresby, VIC, AUS, 3179

Website

https://www.medicaldev.com

Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International (ASX:MVP) Headlines

No Headlines